Bone material properties in trabecular bone from human iliac crest biopsies after 3‐ and 5‐year treatment with risedronate

wbldb

Durchschlag, Erich¹; Paschalis, Eleftherios P.¹; Zoehrer, Ruth¹; Roschger, Paul¹; Fratzl, Peter²; Recker, Robert³; Phipps, Roger⁴; Klaushofer, Klaus¹

Bone material properties in trabecular bone from human iliac crest biopsies after 3‐ and 5‐year treatment with risedronate

J Bone Miner Res. October 2006;21(10):1581-1590

©2006 American Society for Bone and Mineral Research

Affiliations

¹Ludwig Boltzmann Institute of Osteology at the Hanusch Hospital WGKK and AUVA Trauma Centre Meidling, 4th Medical Department, Hanusch Hospital, Vienna, Austria

²Department of Biomaterials, Max Planck Institute of Colloids and Interfaces, Berlin, Germany

³Osteoporosis Research Center, Creighton University, Omaha, Nebraska, USA

⁴Procter & Gamble Pharmaceuticals, Mason, Ohio, USA
Abstract and keywords

Long‐term effects of risedronate on bone mineral maturity/crystallinity and collagen cross‐link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double‐blinded study, 3‐ and 5‐year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy.

Introduction: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long‐term effects of risedronate on bone material properties in humans.

Materials and Methods: Osteoporotic women enrolled in the VERT‐NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross‐link ratio was measured in these biopsies using Fourier transform infrared imaging.

Results: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross‐link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone‐forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone‐forming areas in both indices after 5 years of treatment.

Conclusion: Long‐term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross‐link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contribute to risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.

Keywords: long‐term risedronate treatment; postmenopausal osteoporosis; Fourier transform infrared imaging; mineral maturity/crystallinity; collagen cross‐links
Links

DOI: 10.1359/jbmr.060701

PubMed: 16995813

WoS: 000240810000010
History

Received: 2006-03-6

Revised: 2006-06-8

Accepted: 2006-07-3

Online: 2006-07-10

Cited Works (32)

Year	Entry
2003	Paschalis EP, Boskey AL, Kassem M, Eriksen EF. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res. June 2003;18(6):955-959.
2003	Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL. Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH(1–34) for 18 months. J Bone Miner Res. April 2003;18(4):769-775.
1998	Roschger P, Fratzl P, Eschberger J, Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone. October 1998;23(4):319-326.
1985	Cummings SR. Are patients with hip fractures more osteoporotic? review of the evidence. Am J Med. March 1985;78(3):487-494.
2002	Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three‐dimensional microcomputed tomography. J Bone Miner Res. July 2002;17(7):1139-1147.
2004	Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. April 2004;34(4):736-746.
2005	Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. December 2005;20(12):2097-2104.
1994	Fratzl P, Roschger P, Eschberger J, Abendroth B, Klaushofer K. Abnormal bone mineralization after fluoride treatment in osteoporosis: a small‐angle x‐ray‐scattering study. J Bone Miner Res. October 1994;9(10):1541-1549.
2002	Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. October 16, 2002;288(15):1889-1897.
2002	Eriksen E, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. November 2002;31(5):620-625.
2002	Aparicio S, Doty SB, Camacho NP, Paschalis EP, Spevak L, Mendelsohn R, Boskey AL. Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy. Calcif Tiss Int. May 2002;70(5):422-429.
1999	Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. October 13, 1999;282(14):1344-1352.
2004	Fratzl P, Gupta HS, Paschalis EP, Roschger P. Structure and mechanical quality of the collagen–mineral nano-composite in bone. J Mater Chem. 2004;14(14):2115-2123.
2002	Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. January 2002;17(1):1-10.
1996	Fratzl P, Schreiber S, Roschger P, Lafage M, Rodan G, Klaushofer K. Effects of sodium fluoride and alendronate on the bone mineral in minipigs: a small‐angle X‐ray scattering and backscattered electron imaging study. J Bone Miner Res. February 1996;11(2):248-253.
2003	Gao H, Ji B, Jäger IL, Arzt E, Fratzl P. Materials become insensitive to flaws at nanoscale: lessons from nature. Proc Natl Acad Sci USA. May 13, 2003;100(10):5597-5600.
2000	Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. February 2000;15(2):183-187.
1997	Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of normal human cortical and trabecular bone. Calcif Tiss Int. December 1997;61(6):480-486.
2006	Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RGG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. May 2006;38(5):617-627.
1996	Massé PG, Rimnac CM, Yamauchi M, Coburn SP, Rucker RB, Howell DS, Boskey AL. Pyridoxine deficiency affects biomechanical properties of chick tibial bone. Bone. June 1996;18(6):567-574.
1995	Oxlund H, Barckman M, Ørtoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone. October 1995;17(4)(suppl):S365-S371.
1996	Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human osteonal bone. Calcif Tiss Int. December 1996;59(6):480-487.
1995	Knott L, Whitehead CC, Fleming RH, Bailey AJ. Biochemical changes in the collagenous matrix of osteoporotic avian bone. Biochem J. September 15, 1995;310(3):1045-1051.
2004	Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL. Bone fragility and collagen cross‐links. J Bone Miner Res. December 2004;19(12):2000-2004.
1993	Bailey AJ, Wotton SF, Sims TJ, Thompson PW. Biochemical changes in the collagen of human osteoporotic bone matrix. Connect Tissue Res. 1993;29(2):119-132.
1992	Bailey AJ, Wotton SF, Sims TJ, Thompson PW. Post-translational modifications in the collagen of human osteoporotic femoral head. Biochem Biophys Res Commun. June 30, 1992;185(3):801-805.
2001	Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M. Spectroscopic characterization of collagen cross‐links in bone. J Bone Miner Res. October 2001;16(10):1821-1828.
2003	Paschalis E, Recker R, Dicarlo E, Doty S, Atti E, Boskey A. Distribution of collagen cross-links in normal human trabecular bone. J Bone Miner Res. November 2003;18(11):1942-1946.
1996	Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. May 18, 1996;312(7041):1254-1259.
2000	Jäger I, Fratzl P. Mineralized collagen fibrils: a mechanical model with a staggered arrangement of mineral particles. Biophys J. October 2000;79(4):1737-1746.
1998	Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone. March 1998;22(3):181-187.
1997	Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. Calcif Tiss Int. December 1997;61(6):487-492.

Cited By (22)

Year	Entry
2008	Roschger P, Paschalis EP, Fratzl P, Klaushofer K. Bone mineralization density distribution in health and disease. Bone. March 2008;42(3):456-466.
2010	Gourion-Arsiquaud S, Allen MR, Burr DB, Vashishth D, Tang SY, Boskey AL. Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone. March 2010;46(3):666-672.
2020	Taylor EA, Donnelly E. Raman and Fourier transform infrared imaging for characterization of bone material properties. Bone. October 2020;139:115490.
2022	Paschalis EP, Gamsjaeger S, Klaushofer K, Shane E, Cohen A, Stepan J, Pavo I, Eriksen EF, Taylor KA, Dempster DW. Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values. Bone. September 2022;162:116478.
2013	Boskey AL. Bone composition: relationship to bone fragility and antiosteoporotic drug effects. BoneKEy Rep. December 2013;2:447.
2020	Taylor EA, Donnelly E, Yao X, Johnson ML, Amugongo SK, Kimmel DB, Lane NE. Sequential treatment of estrogen deficient, osteopenic rats with alendronate, parathyroid hormone (1–34), or raloxifene alters cortical bone mineral and matrix composition. Calcif Tiss Int. March 2020;106(3):303-314.
2010	Farlay D, Panczer G, Rey C, Delmas PD, Boivin G. Mineral maturity and crystallinity index are distinct characteristics of bone mineral. J Bone Min Metab. July 2010;28(4):433-445.
2008	Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. January 2008;23(1):6-16.
2010	Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MCH, Weinstein RS, Whyte M. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. November 2010;25(11):2267-2294.
2012	Bala Y, Depalle B, Farlay D, Douillard T, Meille S, Follet H, Chapurlat R, Chevalier J, Boivin G. Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization. J Bone Miner Res. April 2012;27(4):825-834.
2013	Gourion-Arsiquaud S, Lukashova L, Power J, Loveridge N, Reeve J, Boskey AL. Fourier transform infrared imaging of femoral neck bone: reduced heterogeneity of mineral-to-matrix and carbonate-to-phosphate and more variable crystallinity in treatment-naive fracture cases compared with fracture-free controls. J Bone Miner Res. January 2013;28(1):150-161.
2016	Boskey AL, Donnelly E, Boskey E, Spevak L, Ma Y, Zhang W, Lappe J, Recker RR. Examining the relationships between bone tissue composition, compositional heterogeneity, and fragility fracture: a matched case-controlled FTIRI study. J Bone Miner Res. May 2016;31(5):1070-1081.
2008	Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int. March 2008;19(3):329-337.
2008	Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. June 2008;19(6):733-759.
2009	Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int. May 2009;20(5):793-800.
2010	Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2010;21(2):195-214.
2017	Paschalis EP, Gamsjaeger S, Klaushofer K. Vibrational spectroscopic techniques to assess bone quality. Osteoporos Int. August 2017;28(8):2275-2291.
2020	Taylor EA. Validation and Implementation of Vibrational Spectroscopic Measures of Bone Composition [PhD thesis]. Ithaca, NY: Cornell University; December 2020.
2007	Tang SY-C. Effects of Non-Enzymatic Glycation on the Biomechanical Behavior of Bone [PhD thesis]. Troy, NY: Rensselaer Polytechnic Institute; 2007.
2009	Ruppel ME. Alterations in the Mineral and Collagen Matrix of Bisphosphonate-Treated Bone and Osteoblasts [PhD thesis]. Stony Brook, NY: Stony Brook University; May 2009.
2007	MacNeil JAM. Clinical Assessment of Bone Quality [PhD thesis]. Calgary, AB: University of Calgary; June 2007.
2012	Tjhia CKH. Bone Quality of Patients With Atypical Fractures and Severely Suppressed Bone Turnover [PhD thesis]. Davis, University of California; 2012.